Qurient Co., Ltd.

A115180

KR7115180002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 01/07/2024 am IST			5-day change	1st Jan Change
3,500 ^KRW	-1.41%		-6.04%	-25.05%

21/05	Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	CI
17/05	Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI

Qurient Co., Ltd. has withdrawn its IPO in the amount of KRW 29.57 billion.

November 30, 2015 at 10:30 am IST

Qurient Co., Ltd. has withdrawn its IPO in the amount of KRW 29.57 billion.

Offer Details:
Security Type: Common Stock
Offered: 1408000
Price/Range: 18000.00 to 21000.00

Latest news about Qurient Co., Ltd.

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	21/05	CI
Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	17/05	CI
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor	12/04	CI
Qurient Co., Ltd. announced that it has received KRW 5.999997188 billion in funding from Premier Partners, LLC	27/12	CI
Qurient Co., Ltd. announced that it expects to receive KRW 5.99999268 billion in funding from Premier Partners, LLC	19/12	CI
Qurient Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Qurient Co. Ltd. and TB Alliance Announces Exclusive License Agreement for Telacebec	03/23/03	CI
Qurient Co., Ltd. Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors	31/23/31	CI
Qurient Co. Ltd Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01/22/01	CI
Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01/22/01	CI
Qurient Co., Ltd. Enters into A Clinical Collaboration Agreement with Merck & Co., Inc. for Clinical Study of Q901	15/22/15	CI
Qurient Co. Ltd. U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy	08/22/08	CI
Qurient Co., Ltd. announced that it has received KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	17/21/17	CI
Qurient Co., Ltd. announced that it expects to receive KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	09/21/09	CI
Qurient Co. Ltd. Enters into A Clinical Collaboration Agreement with MSD	23/21/23	CI
Qurient Co., Ltd.(KOSDAQ:A115180) dropped from S&P Global BMI Index	07/21/07	CI
Qurient Co., Ltd. Enrolls First Patient in Q702 U.S. Phase 1 Study	26/21/26	CI
Qurient Co., Ltd. announced that it expects to receive KRW 59.99986805 billion in funding from a group of investors	22/20/22	CI
QLi5 Therapeutics GmbH announced that it expects to receive KRW 2.039115 billion in funding from Qurient Co., Ltd.	11/20/11	CI
Qurient Co., Ltd. Announces U.S. FDA Clearance of IND Application for Q702	26/20/26	CI
W Asset Management Co., Ltd. acquired 5.13% stake in Qurient Co., Ltd..	28/19/28	CI
Qurient Co., Ltd. Announces Positive Phase 2a Data of Novel Antibiotic for the Treatment of Tuberculosis	03/19/03	CI
Quad Investment Management Corporation acquired additional 9.1% stake in Qurient Co., Ltd..	23/18/23	CI
Qurient Co., Ltd. announced that it has received KRW 39.9999072 billion in funding	19/18/19	CI
Qurient Co., Ltd. announced that it expects to receive KRW 39.9999072 billion in funding	06/18/06	CI

Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
QURIENT CO., LTD.	-25.05%	85M
MCKESSON CORPORATION	+26.64%	75.76B
CARDINAL HEALTH, INC.	-3.02%	23.95B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+15.84%	8.7B
SINOPHARM GROUP CO. LTD.	+1.47%	8.29B
HUADONG MEDICINE CO., LTD	-32.22%	6.7B
H. LUNDBECK A/S	+17.83%	5.38B
GALENICA AG	+1.17%	4.08B
EBOS GROUP LIMITED	-9.44%	3.79B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-7.80%	3.3B